368 PATENT ABSTRACTS

5177016

M O N O C L O N A L A N T I B O D Y R E C O G N I Z I N G A N T H R A C Y C L I N E

G L Y C O S I D E S P E C I F I C E P I T O P E A N D H Y B R I D O M A S E C E R N I N G

T H E A N T I B O D Y

rein. The protein contains 16 epidermal growth factors (EGF) like repeats, and 3 repeats not found in other proteins. The DNA for the pro- tein is found to contain consensus sequences for hydroxylation of asparagine/aspartic acid residues, and, in the purified protein beta hydro- xylated asparagine residues were found.

Andrea Balsari, Maria I Colnaghi, Mario Ghione, Milan, Italy assigned to Istituto Nazionale per lo Studio e la Cura dei Tumori

A monoclonal antibody against Doxorubicin and other anthracycline derivatives, being the monoclonal antibody able to selectively recognize epitopes located in correspondence or in proximity of the aromatic D ring of the an- thracycline molecule, is described.

5177191

G E L F I L T R A T I O N O F F A C T O R VII I

William J Brockway, Richard Seng assigned to Miles Inc

Highly purified antihemophilic factor can be produced from a cryoprecipitate by a process comprising a PEG precipitation step, a viral in- activation step and a gel filtration step, all steps being carried out at room temperature.

5178858

M E T H O D F O R P R E V E N T I O N O F G R A F T V E R S U S H O S T D I S E A S E

Thomas A Reichert, Richar Champlin

A method is disclosed for the treatment and pre- vention of graft versus host disease in man through the combined use of anti-CD8 mono- clonal antibodies and a CD4+ cell inactivator.

5178859

V A C C I N E A G A I N S T L Y M E D I S E A S E

Markus M Simon, Ulrich E Schaible, Klau Eich- mann, Michae Kramer, Wallic Reinhard, Freiburg, Federal Republic Of Germany as- signed to Max-Planck-Gesellschaft zur Forderung der Wissenschaften e V; Deutsches Krebsforschungszentrum Stiftung des off- entlichen Rech

5177197

I S O L A T E D N U C L E O T I D E S E Q U E N C E E X P R E S S I N G H U M A N T R A N S F O R M I N G

G R O W T H F A C T O R - B E T A 1 - B I N D I N G P R O T E I N

Tetsuto Kanzaki, Anders Olofsson, Anita Moren, Christer Wernstedt, Ulf Hellman, Kohei Miyazono, Lena Claesson-Welsh, CarI-Henrik Heldin, Chiba, Japan assigned to Ludwig In- stitute for Cancer Research

Purified protein known as platelet TGF- betal- BP (transforming growth factor- betal-binding protein) is described. The protein is useful for purposes such as the production of antisera which are useful in identifying complexes con- taining the binding protein, as well as in forma- tion of labeled probes. Also described are purified DNA which expresses the protein, as well as messenger RNA translated into the pro-

The present invention provides a vaccine against Lyme disease, wherein it contains one or more monoclonal antibodies which are specific for the 31 kD antigen (OspA) or the 34 kD antigen (OspB) of Borrelia burgdorferi. The present in- vention also provides a process for obtaining this vaccine, as well as new monoclonal antibodies and antigens.

5178862

C A N I N E D I S T E M P E R V I R U S V A C C I N E A N D M E T H O D O F

P R E P A R A T I O N

Richard G Olsen assigned to Parhelion Corpora- tion

Disclosed is a vaccine for the prevention of dis- ease caused by canine distemper virus (CDV). The vaccine is prepared from CDV immunogens derived from CDV persistently-infected cells cul-